Accordingly, distinguishing the MPR from the Non is of clinical significance, but heterogeneity across the TME in different tumor types under various treatment regimens has hindered current investigations considerably, among which the diversity of CD8+ tumor-infiltrating lymphocytes (TILs) might still be the biggest obstacle. The gene discussed is CD8A; the disease is neoplasm.